Group 1 - The technology opens new avenues for treating refractory mental illnesses, including treatment-resistant depression, obsessive-compulsive disorder, and tic disorders [1][3] - A case study from Ruijin Hospital highlights a 32-year-old patient with a 16-year history of depression who benefited from a novel therapy combining deep brain stimulation (DBS) and brain-computer interface (BCI) technology [1] - The innovative treatment involves the implantation of two electrodes with 16 stimulation contacts into the brain's emotional circuit, allowing for precise modulation and breaking the cycle of depression [1][3] Group 2 - The DBS combined with BCI technology is a minimally invasive intervention that avoids the memory loss associated with electroconvulsive therapy and the side effects of long-term medication [3] - This new therapy has already been clinically applied to over 30 cases, providing a new option for treatment-resistant depression patients [3] - Depression is increasingly recognized as a significant mental health issue, particularly among younger populations, with a reported prevalence of 15% to 20% among adolescents in China [3]

D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday.The analyst upgraded from Hold to Buy and introduced a price forecast of $20.Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) with the lead program.”ART27.13 is a Phase 2 asset, a selective benzimadazole agonist acquired from AstraZeneca Plc AZN.The analyst wrote that ART27.13 showed potential to stimulate appetite and promot ...

Company Overview - Brainsway Ltd. shares (BWAY) experienced a 5.3% increase, closing at $11.49, with notable trading volume compared to typical sessions [1] - The company is expected to report quarterly earnings of $0.04 per share, unchanged from the previous year, with revenues projected at $12.39 million, reflecting a 23.8% increase year-over-year [3] Clinical Trial Results - The recent rise in BWAY shares is linked to positive market sentiment following successful clinical trial results for BrainsWay's accelerated Deep TMS therapy for Major Depressive Disorder (MDD) [2] - The multicenter, randomized study showed statistically significant improvements in depression symptoms, a favorable safety profile, and rapid onset of effect, positioning BrainsWay's technology as a leading non-invasive treatment option for MDD [2] Earnings Estimates and Market Sentiment - The consensus EPS estimate for Brainsway has been revised 10% higher in the last 30 days, indicating a positive trend that typically correlates with price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [5] Industry Comparison - Brainsway operates within the Zacks Medical - Products industry, where Boston Scientific (BSX) also competes, having closed 1.1% higher at $102.36, but with a -3.1% return over the past month [5] - Boston Scientific's consensus EPS estimate has increased by 0.1% to $0.72, representing a 16.1% change compared to the previous year [6]

Core Viewpoint - Compass Pathways' disappointing Phase III trial results for psilocybin treatment of treatment-resistant depression (TRD) led to a significant decline in stock prices across the psychedelic drug sector, with Compass's stock dropping by 49% [1][2]. Group 1: Trial Results and Market Reaction - The Phase III trial (COMP005) for COMP360 showed a MADRS score improvement of only 3.6 points compared to placebo, which, while statistically significant, fell short of analysts' expectations of at least 5 points and was lower than the company's previous Phase II data of 6.6 points [2][3]. - The underwhelming results raised concerns about the efficacy, sustainability, and commercial potential of psilocybin, leading to a broader sell-off in the psychedelic drug sector [2][3]. - Other companies in the psychedelic space, such as atai Life Sciences, MindMed, Cybin, and GH Research, experienced stock declines ranging from 5% to over 15% following the news [2][3]. Group 2: Impact on Other Companies - atai Life Sciences, with its DMT oral film in Phase II trials for TRD, saw its stock drop by over 15% [3]. - MindMed, which is in Phase III trials for an LSD derivative targeting major depressive disorder, experienced a stock decline of approximately 6% [3]. - Cybin's stock, which is developing an oral psilocin treatment for depression in Phase II trials, fell by about 5% [3]. - GH Research, with its inhaled mebufotenin candidate in Phase II for TRD, also saw a stock decrease of around 5% [3]. - Other psychedelic stocks, including Clearmind Medicine, Enveric Biosciences, and Bright Minds Biosciences, faced significant declines on the same day [4].

我的临床工作主要是处理病人或者各种来访者情绪方面的问题。我们都有悲欢离合，也经常会有各种各样的不良情绪。 2020年的五月份，一位30多岁的女孩来到了诊室。她告诉我，近两年她掉入了人生的最低谷，经历了很多事情，包括妈妈做手术，四位长辈住院，还有一 位师长去世。 她的情绪非常沮丧，说她两年来不想动、不想说话、不想理人，看世界都是灰色的，没有精神，注意力没法集中，经常有轻生的想法，于是她求助过好几 位医生，医生开过很多抗郁药给她，但是她并没有从抗抑郁药中获益，情绪一直没有好转。 ▲ 情绪的"跷跷板" 后来她看了我的一本书，于是画了这个图，从这个图可以看到她人生情绪的经历。 在她上幼儿园的时候，父母就离异了，但是父母的离异似乎没有给她的情绪带来太多的影响；小学阶段，她的心情一直都很好，她形容她的小学阶段总体 是开心的，过着无忧无虑的生活，仅是偶有不快。 在初中时有过一段情绪低落的经历，那时她首次有了自杀的念头，她形容那时候的情绪低落并没有任何原因，后来经历了一次友情的叛变，她的情绪一下 子又掉到低谷里去了。 但是到了高中，她的情绪又上了快车道，她形容高中阶段是人生最美妙的阶段，那时候很愉悦，觉得无比幸福，看什么事情 ...

Core Viewpoint - The conference focused on the relationship between depression and insomnia, highlighting the importance of integrated treatment approaches using both traditional Chinese medicine and Western medicine to improve patient outcomes [1][2][4]. Group 1: Conference Overview - The "Chronic Disease Prevention and Treatment in China" conference was held on June 21, combining online and offline formats across Changsha, Wuhan, and Guangzhou, attracting hundreds of experts in mental health [1]. - Professor Zhang Honggeng presented a report on the understanding of "depression and insomnia" from both Chinese and Western medical perspectives, emphasizing the clinical effectiveness of innovative Chinese herbal medicines [1][3]. Group 2: Relationship Between Depression and Insomnia - Depression is characterized by persistent low mood lasting at least two weeks, while insomnia involves difficulty in falling or maintaining sleep for 2-3 weeks, both of which are interrelated [2]. - Approximately 40%-90% of depression patients experience insomnia symptoms, and 71.7% of those treated with antidepressants still have residual insomnia symptoms [2]. - Insomnia increases the risk of developing depression by 183%, anxiety disorders by 223%, and suicide risk by 67%, indicating a bidirectional relationship between the two conditions [2]. Group 3: Treatment Approaches - The conference highlighted the unique advantages of traditional Chinese medicine in identifying and treating depression and insomnia through personalized treatment plans [2][4]. - Innovative Chinese herbal medicines such as "Jieyu Chufan Capsule" and "Yishen Yangxin Anshen Tablet" were discussed for their significant clinical applications in treating different types of depression and insomnia [4]. - The "Jieyu Chufan Capsule" is effective for patients with symptoms like dizziness, chest tightness, and anxiety, while the "Yishen Yangxin Anshen Tablet" is recommended for patients with insomnia due to deficiency syndromes [4]. Group 4: Integration of Treatment Methods - The necessity of combining traditional Chinese and Western medicine for treating depression and insomnia was emphasized, as this approach can enhance treatment efficacy and reduce side effects [4].

"不刷手机就会觉得特别烦躁，生活特别空虚，甚至影响睡眠。如果老年人出现这些现象，意味着可能 已经出现了医学领域所称的'行为成瘾'特征。"王华丽说。 手机等数字工具的应用在提升老年人生活便利度、丰富生活内容等方面发挥了积极作用，但成瘾后，在 身体方面，会造成老年人眼肌疲劳、影响视力，加重颈椎、肩颈的负担，导致颈椎病、肩周炎等疾病转 重；在心理方面，由于长期难以保持与其他人的人际交往水平，难以维持健康的生活节奏，老年人放下 手机后往往会受到不良情绪的困扰。 "一些网络信息平台还会向老年人推送负面不良信息，造成老年人误判误解，这对他们的身心健康会产 生更不好的影响。"王华丽建议，老年人使用手机时，在内容的选择上要有所辨别。家里人可以帮助他 们设置相关提醒，关闭一些无关紧要的推送。 "如果家里有老年人明显出现了沉迷短视频的现象，可以带他去精神科或心理科进行评估、咨询，进行 必要的治疗。"王华丽表示，老年人的心理健康问题应得到及时关注。 研究显示，约半数老年抑郁症患者到医院就诊的首次症状不是心情不好、抑郁等典型表现，而是各种各 样的身体不舒服。 "有一些老年人多次去医院看病，反复说身体不舒服，胸闷、乏力、头晕、食欲不好 ...

中经记者孟庆伟北京报道 "我们要正确识别'身体假象'背后的心理实质，这样才能帮助提升老年人的生活质量，让他们的晚年生 活更加幸福。"6月20日，在国家卫健委举行的"时令节气与健康（夏至）"发布会上，北京大学第六医院 研究员王华丽就老年人的心理与健康问题作出上述呼吁。 6月23日至29日是"全国老年健康宣传周"，今年的活动主题是"银龄健康，从心启航"。 王华丽表示，临床中常发现不少老年人反复到医院就诊，主诉胸闷、乏力、头晕、食欲不振、失眠等身 体不适症状，但各项检查却未见明显异常。这种情况常使老人被家人误解为"没病找病"或"娇气、不坚 强"。 （文章来源：中国经营报） 王华丽建议，当老年人反复诉说各种身体不适，在排除躯体疾病后，应特别关注他们的心理状态，观察 其是否表现闷闷不乐、兴趣减退、愉悦感缺失，或反应迟缓、思维困难；有的老人可能出现失眠或嗜 睡、食欲不佳、体重下降等问题，遇到这些情况应及时就诊。 她呼吁，老年人应关注自身身心健康，家人也应给予更多的心理关爱，深入了解老人内心的需求，必要 时陪伴其到医院寻求专业帮助。 与此同时，智能手机的普及和短视频平台的兴起，导致老年人频繁刷手机现象增多，引发社会关注。 ...

Supernus Pharmaceuticals (SUPN) M&A Announcement June 16, 2025 08:30 AM ET Speaker0 Good morning, everyone, and welcome to Sperna's Business Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Bassa, Investor Relations representative for Abertis Pharmaceuticals. You may begin. Sp ...

Sage Therapeutics (SAGE) M&A Announcement June 16, 2025 08:30 AM ET Speaker0 Good morning, everyone, and welcome to Sperna's Business Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to Peter Bassa, Investor Relations representative for Abertis Pharmaceuticals. You may begin. Speaker1 ...